This Article Free upon publication Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Panel Articles by Turpie, A. G. G. Search for Related Content PubMed PubMed Citation Articles by Panel, Articles by Turpie, A. G. G.

(Stroke. 1997;28:1501-1506.)
© 1997 American Heart Association, Inc.

Articles

Etiology of Stroke

Panel
J. P. Mohr, MD, Chair; Gregory W. Albers, MD; Pierre Amarenco, MD; Viken L. Babikian, MD; José Biller, MD; Robin L. Brey, MD; Bruce Coull, MD; J. Donald Easton, MD; Camilo R. Gomez, MD; Cathy M. Helgason, MD; Carlos S. Kase, MD; Patrick M. Pullicino, MD; Alexander G. G. Turpie, MD

Key Words: AHA Medical/Scientific Statements • stroke • prevention • embolism • thrombosis

	Introduction

 
The diagnosis of arterial stroke differentiates ischemia from hemorrhage. The former may be due to arterial occlusion or stenosis, the latter to leakage or rupture of an artery. Computed tomography (CT) and magnetic resonance imaging (MRI) have shown that this basic differentiation cannot be reliably made from the history and clinical examination alone. Of the clinical stroke syndromes, only Wallenberg's syndrome has not been reported to be due to hemorrhage. When CT or MRI is not available for diagnosis, spinal tap is reliably positive only when the aneurysm or arteriovenous malformation has ruptured into the subarachnoid space; the results are often normal when a small hemorrhage occurs in the parenchyma. For some therapies, notably neuroprotective agents, the potential benefits for ischemia do not seem to be offset by potential harm in the case of hemorrhage. However, because fibrinolytics, antithrombotic agents, or surgery are treatment options, diagnostic certainty is essential to avoid harming the patient.

Most—but not all—strokes have a sudden or rapidly evolving onset. Differential diagnosis of sudden change in focal neurological status includes seizures or postepileptic paralysis, hemorrhage into a tumor (itself a form of stroke), and migraine. Neuroimaging helps to differentiate between these and the cause of short-lived symptoms (transient ischemic attack [TIA]) usually presumed due to ischemia but possibly due to new-onset infarction or hemorrhage. More precise classification of stroke into a pathogenic subtype (embolism, thrombosis, decreased perfusion or "lacunar" infarction, leakage, or rupture) evades the best clinical skills.

	Diagnosis of Ischemic Stroke Mechanism

 
The classification of stroke mechanism depends on the . . . [Full Text of this Article]

This article has been cited by other articles:

				H. Kimm, J. E. Yun, J. Jo, and S. H. Jee Low Serum Bilirubin Level as an Independent Predictor of Stroke Incidence: A Prospective Study in Korean Men and Women Stroke, November 1, 2009; 40(11): 3422 - 3427. [Abstract] [Full Text] [PDF]

				P. Amarenco, O. Benavente, L. B. Goldstein, A. Callahan III, H. Sillesen, M. G. Hennerici, S. Gilbert, A. E. Rudolph, L. Simunovic, J. A. Zivin, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes Stroke, April 1, 2009; 40(4): 1405 - 1409. [Abstract] [Full Text] [PDF]

				H. Sillesen, P. Amarenco, M. G. Hennerici, A. Callahan, L. B. Goldstein, J. Zivin, M. Messig, K. M. Welch, and on Behalf of the SPARCL Investigators Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial Stroke, December 1, 2008; 39(12): 3297 - 3302. [Abstract] [Full Text] [PDF]

				P. Amarenco and P. G. Steg Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention Eur. Heart J., July 1, 2008; 29(13): 1605 - 1607. [Full Text] [PDF]

				U. K. Sampson, M. A. Pfeffer, J. J.V. McMurray, Y. Lokhnygina, H. D. White, S. D. Solomon, and for the Valsartan in Acute Myocardial iNfarcTion ( Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial Eur. Heart J., March 2, 2007; 28(6): 685 - 691. [Abstract] [Full Text] [PDF]

				M. J. Alberts, R. E. Latchaw, W. R. Selman, T. Shephard, M. N. Hadley, L. M. Brass, W. Koroshetz, J. R. Marler, J. Booss, R. D. Zorowitz, et al. Recommendations for Comprehensive Stroke Centers: A Consensus Statement From the Brain Attack Coalition Stroke, July 1, 2005; 36(7): 1597 - 1616. [Abstract] [Full Text] [PDF]

				Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Stroke, April 1, 2000; 31(4): 1002 - 1012. [Full Text] [PDF]

				Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Circulation, March 28, 2000; 101(12): 1483 - 1493. [Full Text] [PDF]